论文部分内容阅读
伏立康唑是治疗侵袭性真菌感染的一线药物,具有非线性药动学特征。现有的有关伏立康唑治疗药物浓度监测的研究表明,其临床意义虽重大,但均是单中心的小样本研究,有一定的局限性。一项多中心回顾性研究探讨了伏立康唑浓度与临床疗效和不良反应的关系,并评价了可能影响伏立康唑浓度的临床因素和药物相互作用因素。入选2008年12月—2010年5月在澳大利亚的7所医院接受伏立康唑治
Voriconazole is the first-line drug for the treatment of invasive fungal infections and has nonlinear pharmacokinetic properties. The existing research on voriconazole treatment drug concentration monitoring shows that although its clinical significance is significant, it is a single-center small sample study with some limitations. A multi-center retrospective study examining the relationship between voriconazole concentration and clinical efficacy and adverse reactions was performed and the clinical and drug interaction factors that may affect the voriconazole concentration were evaluated. Selected from December 2008 to May 2010 in voriconazole at seven hospitals in Australia